Medical Oncologist | Consultant | Professional Coach
Joined June 2020
- Tweets264
- Following418
- Followers405
- Likes1.2K
MinhTri Nguyen, MD (he/him) retweeted
🎙️On this episode of #BreastCancerBriefing, @SaraNunneryMD, of @TNOncology and @MinhTriMD,
discuss the emergence of the oral SERD giredestrant in hormone receptor–positive, HER2-negative breast cancer management. #bcsm #oncology
Listen here 📷➡️ onclive.com/view/esr1-mutati…
MinhTri Nguyen, MD (he/him) retweeted
Tremendous discussion by @drsarahsam, highlighting the promise of several escalation/substitution strategies across breast cancer subtypes, but reminding the costs and caveat of each new option. #ASCO26
MinhTri Nguyen, MD (he/him) retweeted
Dates, timings and locations of some of the key breast cancer presentations at @ASCO #ASCO2026 @OncoAlert
MinhTri Nguyen, MD (he/him) retweeted
Dato-DXd now approved for the 1L treatment of IO-ineligible mTNBC.
For most pts, both Dato-DXd & SG will be adequate choices.
For some, based on the data, Dato-DXd may be preferred:
-recurrence <6 mo
-symptomatic / response needed
-brain mets
-living far from hospital (Q3W)
A good read for those in medicine and leaders alike (or both).
#Medicine #MedTwitter #Residency #PhysicianLeadership
Powerful editorial on corporitization of medicine.
1. Trainees are not cheap labor
2. Margin focus threatens trust.
3. Leaders need to stay in touch with clinical care
nejm.org/doi/full/10.1056/NE…
MinhTri Nguyen, MD (he/him) retweeted
My favorite study today at #ESMOBreast: PREcoopERA (IBCSG 67-22), a window-of-opportunity trial in premenopausal ER+/HER2- early BC asking whether giredestrant alone is enough, or whether ovarian suppression is still required.
231 patients → giredestrant alone, G + triptorelin, or anastrozole + triptorelin. Primary endpoint: Ki67 at 4 weeks.
Giredestrant alone did NOT meet non-inferiority vs G+OS (-68% vs -80%). And G+OS was not superior to anastrozole+OS (p=0.18).
Bottom line: Even for a next-gen SERD, ovarian suppression adds to anti proliferation effect in premenopausal patients.
#ESMOBreast #BreastCancer #Giredestrant
MinhTri Nguyen, MD (he/him) retweeted
In rural health care, the path to a timely breast cancer diagnosis and treatment is often blocked by an accumulation of obstacles, according to MinhTri Nguyen, MD.
Watch more ➡️ hubs.li/Q04fDpyn0
#bcsm #BreastCancer #oncology | @MinhTriMD
MinhTri Nguyen, MD (he/him) retweeted
Ovarian function suppression is arguably the most important advancement for ER+ young women with breast cancer, markedly reducing recurrence.
Now more trials on how to support side effects for these women thrown into early menopause. #bcsm
Effects of ovarian ablation or suppression on breast cancer recurrence and survival: patient-level meta-analysis of 15 000 women in 23 randomised trials - The Lancet thelancet.com/journals/lance…
MinhTri Nguyen, MD (he/him) retweeted
FDA approves vepdegestrant for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer
This Post is from an account that no longer exists. Learn more
Trial design insufficient to answer the clinical question (Not that Cami isn't effective -PFS hazard ratio of 0.44 is real). The question: whether ctDNA-guided early switching is better than switching at radiographic progression. Awaiting the PDUFA date and FDA final say.
fda.gov/media/192156/downloa…
There will be people who agree & disagree with @US_FDA decision on #SERENA6 #cami, but fantastic document by FDA 👏 educating & clearly outlining reasons for the decision and how PFS2 will be interpreted.
A must read for drug developers and pharma.
MinhTri Nguyen, MD (he/him) retweeted
Very important data. Even in the absence of oral SERD at crossover, there is no apparent OS benefit as yet for switch based on molecular ESR1mut detection without radiological progression. And in current practice, all patients would get an oral SERD at radiological/clinical PD
Just admiring the work I don’t have the talent to do… that’s all. 💀
One of our editorial board members @MinhTriMD joined us at our opening to talk all things breast cancer!
MinhTri Nguyen, MD (he/him) retweeted
Grateful to Join the Discussion on the Questions Shaping Breast Oncology - MinhTri Nguyen (@MinhTriMD)
oncodaily.com/voices/minhtri…
#OncoDaily #Oncology #Cancer #Health #Medicine #MedX #MedTwitter
MinhTri Nguyen, MD (he/him) retweeted
Personalizing Therapy in ESR1-Mutated Metastatic Breast Cancer - MinhTri Nguyen (@MinhTriMD)
oncodaily.com/voices/minhtri…
#OncoDaily #Oncology #Cancer #Health #Medicine #BreastCancer
MinhTri Nguyen, MD (he/him) retweeted
1/2📢Now out in @TheLancetOncol 📢
🔹Burnout now impacts 𝟱𝟵% of U.S. oncologists—up from 45% in 2013. This is no longer just a workforce issue—it’s a patient care crisis.
🔹Proud to join @ASCO, @COSAoncology & @EuropeanCancer in this global call to action for thriving, sustainable cancer care workplaces.
🔹Links below. #ClinicianWellbeing #Oncology #HealthWorkforce #burnout
Alongside @COSAoncology & @EuropeanCancer we have joined forces to issue a statement on healthy workplace cultures in the global oncology workforce.
Read the full statement in @TheLancetOncol: brnw.ch/21wVEz9
MinhTri Nguyen, MD (he/him) retweeted
Very big news out today-- adjuvant abemaciclib improves overall survival in high-risk ER+ breast cancer at ~7 yrs of f/u! Showing OS benefit in this setting is not easy & nice to see what an incredible impact adj cdk4/6i can have for our patients!
prnewswire.com/news-releases…
MinhTri Nguyen, MD (he/him) retweeted
A subset of patients with HER2+ metastatic breast cancer are cured by current therapies. Can we increase the rate of cured patients with patient selection & sequential use of the best anti-HER2 agents currently available? High hopes in the #SAPPHO phase 2 trial to bring answers.
The new #SAPPHO study, led by @DFCI_BreastOnc & @TheTBCRC, is evaluating a novel treatment approach for HER2+ #MetastaticBreastCancer. The study will help investigators understand if giving sequential treatments is safe and effective for patients with newly diagnosed HER2+ #MBC, and if maintenance treatment can be safely interrupted.
For more information call 877-338-7425 or visit: dana-farber.org/clinical-tri…
PI: @nlinmd #BreastCancer
MinhTri Nguyen, MD (he/him) retweeted
It was a privilege to work on this review with you @KimmieNgMD
We highlight the rise in young-onset gastrointestinal cancers—current understanding, practical considerations, and future directions.
Honored to co-author this review article in @JAMA_current about the alarming rise in young-onset gastrointestinal cancers with @ThejusJay @DFarberYoungCRC @DanaFarberNews @DanaFarber